Repligen Acquires BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Presence
Repligen has agreed to acquire cell therapy company BioLife Solutions in a $1.5 billion deal valued at $31 per share, combining cash and stock. The acquisition is expected to close by the fourth quarter after regulatory approvals and aims to strengthen Repligen's position in bioprocessing. Management anticipates immediate financial benefits with over $20 million in first-year synergies.
Topics: biotech cell_therapy corporate_development